anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Subjects in the FS group will be operated by Lichtenstein technique, with mesh fixation by fibrin sealant. Subjects in control group will be operated with conventional Lichtenstein technique (mesh fixation by sutures).

Hernia repair will be performed according to standardized Lichtenstein technique, a technique for tension free hernioplasty. A Polypropylene, heavyweight, macroporous mesh will be used (8x15 cm) tailored to individual patients requirement. The different ways of mesh fixation will be randomly assigned within 24 hours before the operation. In the FS group, the two tails of the mesh will be fixed together in overlapping their edges and by surrounding the cord. The edges will be joined up to by 1 suture. No other sutures will be used. First the mesh will be put correctly in place. A small spot (0.5ml) of FS will be applied on the pubis under the mesh without spray then the remaining part (3,5ml) over the mesh on the entire surface in a thin uniform layer by spray. 2 ml Tissucol-Tisseel (4 ml of fibrin sealant) will be used per mesh. In the control group, the mesh will be fixed in a conventional manner. Nerve resection (if occurred) will be recorded; it should be avoided.
A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient are disclosed. A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient are disclosed. A compressed-air energy storage system according to embodiments of the present invention comprises a reversible mechanism to compress and expand air, one or more compressed air storage tanks, a control system, one or more heat exchangers, and, in certain embodiments of the invention, a motor-generator. The reversible air compressor-expander uses mechanical power to compress air (when it is acting as a compressor) and converts the energy stored in compressed air to mechanical power (when it is acting as an expander). In certain embodiments, the compressor-expander comprises one or more stages, each stage consisting of pressure vessel (the "pressure cell") partially filled with water or other liquid. In some embodiments, the pressure vessel communicates with one or more cylinder devices to exchange air and liquid with the cylinder chamber(s) thereof. Suitable valving allows air to enter and leave the pressure cell and cylinder device, if present, under electronic control.
The invention relates to a medicine with protective function on gastric mucosa and liver injury. The medicine is prepared from the following raw materials in parts by weight: 2.80-6.20 parts of rhizoma bletillae, 0.80-4.20 parts of sanqi, 1.80-6.20 parts of vine root, 1.40-4.20 parts of immature bitter orange, 1.80-6.20 parts of white paeony root and 0.80-4.20 parts of liquorice. The invention also discloses a method for preparing the medicine with the protective function on gastric mucosa and liver injury. The medicine can make harmony of stomach, clear liver fire, enhance the immunity of the organism and improve local blood circulation, thus having higher value on health care of people. The medicine is used for patients with liver injury or gastric mucosa injury. Compared with the existing traditional Chinese medicine, the medicine has more remarkably curative effect, and the action of treating chemical liver injury and gastric mucosa injury is obviously superior to a control drug.
Smoking is the leading preventable cause of illness and death. American Indians (AIs) have the highest rate of smoking but very little research has addressed how to help AIs quit smoking. AIs also suffer health disparities related to the addictive use of commercial tobacco. Many AIs also use natural tobacco for ceremonial purposes in addition to using commercial tobacco in an addictive manner. This study will add important new knowledge about how best to help AI smokers quit smoking (addictive use of commercial tobacco) and this is expected to help reduce the prevalence of smoking and smoking-related illness in AI communities. The "Menominee Smoking Cessation Clinical Trial" is a community-based study designed to evaluate a culturally-appropriate, evidence-based smoking cessation intervention for AI smokers. This project joins together collaborators at the University of Wisconsin Center for Tobacco Research and Intervention (UW-CTRI; PI Dr. Stevens Smith; smoking cessation expertise), the UW Carbone Comprehensive Cancer Center (UWCCC), the University of Wisconsin-Milwaukee (UWM; Dr. Leah Arndt; qualitative analysis expertise), and the Menominee Tribal Clinic (MTC; Wellness Director Mr. Mark Caskey; MTC Director Mr. Jerry Waukau, an enrolled member of the Menominee Tribe; and Ms. Jodi Fossum, an enrolled member of the Menominee Tribe) that serves Menominee and other AI patients. The study will randomize 150 AI smokers to two treatment conditions: (1) a standard evidence-based smoking cessation treatment condition (FDA-approved varenicline for 12 weeks + 4 counseling sessions), and, (2) a culturally-tailored smoking cessation treatment condition consisting of the standard treatment (FDA-approved varenicline for 12 weeks + 4 counseling sessions) plus culturally-appropriate treatment elements. Follow-up will be conducted at 3 and 6 months post-quit to assess smoking status and other study outcomes. We also plan to collect and analyze qualitative data (this aspect of the study will be led by Dr. Arndt) to learn more about the process and factors associated with cessation of commercial tobacco in American Indians including cultural factors.
The invention provides a GLP-1 analogue and application thereof, wherein the amino acid sequence of the GLP-1 analogue is one of sequences of SEQ ID NO. 1-SEQ ID NO. 6 and SEQ ID NO. 8-SEQ ID NO. 10. The GLP-1 analogue has strong agonistic activity on a human GLP-1 receptor and high stability, and has the pharmacokinetic characteristic of once-a-day or once-a-week administration. The invention is a variant designed based on the bullfrog GLP-1 sequence, and has excellent weight and lipid reducing effects while retaining the therapeutic effect of GLP-1 analogues on diabetes; the preparation method has greater potential in the aspect of preparing medicaments for treating metabolic syndrome, such as diabetes, obesity, dyslipidemia and other diseases.
The invention relates to a soft capsule for eliminating phlegm and stopping cough and a preparation method. The soft capsule comprises a soft capsule shell and a content. The content includes ledum oil, chlorogenic acid, glycyrrhizic acid and maize oil. The ledum oil in the invention, which is used as a monarch drug, has the functions of eliminating phlegm and preventing inflammation, can get right macrophage in the bronchiole and alveoli in the lung, increase the immune globulin lgA in respiratory tract secretion substances, clean the respiratory tract and enhance the immunity, thereby playing the functions of antivirus and antibacterium, and finally achieving the purposes of eliminating phlegm, stopping cough and relieving asthma. The chlorogenic acid used as a ministerial drug assists the ledum oil to achieve the efficacy of eliminating phlegm and stopping cough by the biological efficacy of clearing away heat and toxic materials. The glycyrrhizic acid in liquorice has the functions of invigorating the spleen and benefiting qi, clearing away heat and toxic materials, eliminating phlegm and stopping cough, relieving pain and attempering medicines, thereby playing the functions of adjuvant drugs and conductant drugs.
There are no data on the presence of estazolam in human milk. Estazolam is present in animal milk. When a drug is present in animal milk, it is likely that the drug will be present in human milk. There are reports that sedation, poor feeding and poor weight gain in infants exposed to benzodiazepines through breast milk. The effects of estazolam on milk production are unknown. Because of estazolam's long half-life, the potential for estazolam to accumulate in breast milk, and the potential for serious adverse reactions, including sedation and withdrawal symptoms in breastfed infants, advise patients that breastfeeding is not recommended during treatment with estazolam.
Drug-induced immune thrombocytopenia is an adverse reaction marked by accelerated destruction of blood platelets. In cancer therapy, thrombocytopenia has many other causes including bone marrow suppression induced by chemotherapeutic agents, infection, and progression of cancer; drug-induced thrombocytopenia can easily be misdiagnosed or overlooked. Here, we present a case of an ovarian cancer patient with a history of mixed connective tissue disease who underwent surgery followed by treatment with paclitaxel, cisplatin, and bevacizumab. The patient developed acute isolated thrombocytopenia after the sixth cycle. Serum antiplatelet antibody testing revealed antibodies against glycoprotein IIb. After we analyzed the whole therapeutic process of this patient, drug-induced immune thrombocytopenia was assumed, and bevacizumab was conjectured as the most probable drug. Thrombocytopenia was ultimately successfully managed using recombinant human thrombopoietin, prednisone, and recombinant human interleukin-11. We provide a summary of existing literature on immune thrombocytopenia induced by bevacizumab and discuss related mechanisms and triggers for drug-induced immune thrombocytopenia. The present case underscores the potential of bevacizumab to induce immune-mediated thrombocytopenia, emphasizing the need for heightened vigilance towards autoimmune diseases or an autoimmune-activated state as plausible triggers for rare drug-induced immune thrombocytopenia in cancer therapy.
A composition used for treating skin maladies, e.g. acne and seborrheic dermatitis, comprises fibrous boehmite, sodium thiosulphate, resorcinol, salicylic acid, and alcohol in specified proportions by weight and in the form of a thixotropic aqueous mixture having a ph of 4 to 6.5.  The composition may contain menthol and/or camphor and a chelating agent, e.g. sodium EDTA. The composition us stated to be compatible with conventional medicaments used in the treatment of acne, of which several examples are given. Aluminium chloride and aluminium potassium sulphate may also be added to the composition.  The alcohol may be an alkanol of 1 to 4 carbon atoms, an alkylene glycol of 2 to 4 carbon atoms, or mixture thereof. The fibrous boehmite used is that described in U.S.A.-Specification 2,915,475.
Stroke is a leading cause of death and permanent disability. About 795,000 strokes occur in the US each year and more than seven million Americans are living with effects of stroke. Cardiovascular diseases are commonly presented and are primary causes of death in stroke survivors. Numerous studies have proven the benefits of walking or other forms of aerobic exercise for cardiovascular and pulmonary function in people after stroke. This proposed randomized controlled efficacy trial will primarily examine whether the investigators' gait training can improve the cardiovascular system in non-ambulatory chronic stroke survivors better than a sitting leg cycling exercise. The investigators have recently developed a novel gait training device and a training program. The experimental group in the proposed project will undergo an 8-week gait training program using a treadmill with body-weight support and the investigators' novel gait training device. The control group will receive an 8-week sitting leg cycling exercise program with similar exercise intensity, frequency, and duration. The proposed project will examine differences between the two groups using a set of comprehensive outcome assessments of cardiovascular, pulmonary, and sensorimotor functions.
The invention provides a compound medicine with an antioxidant function and a preparation method thereof and belongs to the field of Chinese pharmaceutical manufacturing. The compound medicine is prepared by mixing extracts of raw medicines and pilose asiabell root selenium-containing polysaccharide, wherein the mass ratio of the extracts to the pilose asiabell root selenium-containing polysaccharide is 1:(0.05-0.2). The raw medicines comprise pilose asiabell roots, radix angelicae sinensis, fructus lycii, cochinchnese asparagus roots and radix et rhizoma rhei. The compound medicine has a strong ability of scavenging free radicals and can treat or relieve various diseases caused by low antioxidant capacity of a body. The preparation method comprises the following steps that the raw medicines are mixed by weight parts, and the mixed raw medicines are extracted by means of a solvent extraction method, filtered and concentrated to obtain the extracts; the extracts are mixed with the pilose asiabell root selenium-containing polysaccharide to obtain a mixture, and the obtained mixture is prepared into a medicament. The method adopts the solvent extraction method to extract the raw medicines for further mixing with the pilose asiabell root selenium-containing polysaccharide, the process is simple, and the method is suitable for massive production.
PURPOSE:To obtain the subject composition making an antimicrobial germicide stay in the oral cavity for a long period and exhibiting excellent inhibiting effects on the formation of bacterial plaques and preventing effects on gingivitis by blending a composition containing a nonionic antimicrobial germicide with a specific amphoteric surfactant. CONSTITUTION:A composition for the oral cavity is obtained by blending a composition containing a nonionic antimicrobial germicide such as trioxane blended therein with at least one or more amphoteric surfactants (e.g. 2-undecyl-N-carboxymethyl-N-hydroxyethylimidazolinium betaine or 2-undecyl-N-carboxyethyl-N- hydroxyethylimidazolinium betaine) expressed by formulas I and II[R is 1-18C alkyl; (n) and (m) are 1-10]. The composition for the oral cavity iscapable of exhibiting high inhibiting effects on the formation of bacterial plaques and preventing effects on gingivitis. An alkyl sulfate-based compound(e.g. sodium lauryl sulfate or sodium myristyl sulfate) is preferably further addedto the composition.
This will be a double-blinded, placebo-controlled interventional trial. Participants will be 65 years or older who present to the NYU voice center for voice complaints and desired voice therapy for improved vocal performance. Upon enrollment, participants will undergo evaluation for measures of vocal function (acoustic and aerodynamic measures of voice production), laryngeal physiology (electroglottography, videostroboscopy), and voice-associated quality of life (voice handicap index 10 , OMNI vocal effort scale, aging voice index). Participants will be randomized to receive either daily oral creatine supplementation or placebo. After 4 weeks, repeat measures will be taken. At this time, participants will initiate a standard-of-care course of voice therapy directed at improved vocal strength and endurance. The duration of therapy will be approximately 6 weeks. Participants will continue creatine supplementation or placebo through the course of therapy and repeat measures will be assessed at the conclusion of voice therapy. This will mark the end of the study period for each subject.
NS4B is one of the non-structural proteins of classical swine fever virus. By using functional genetics, we have discovered, in the predicted amino acid sequence of NS4B of CSFV strain Brescia, a motif that resembles those found in the toll-like receptor (TLR) proteins, a group of host cell proteins involved in the development of anti-viral mechanisms. We have located the TLR motif in two groups of amino acid triplets at amino acid positions 2531 -3 (residues IYK) and 2566-8 (residues VGI) of the CSFV NS4B glycoprotein. We have constructed a recombinant CSFV (derived from an infectious clone containing the genetic information of the highly virulent strain Brescia) containing amino acid substitutions in the three amino acid residues at positions 2566, 2567 and 2568, where the VGI triplet has been replaced by an AAA triplet inside the NS4B glycoprotein. The obtained virus, named NS4B-VGIv, was completely attenuated in swine, showing a limited ability in spreading during the infection  in vivo . Although attenuated, NS4B-VGIv efficiently protected swine from challenge with virulent BICv at 3 and 28 days post-infection.
Includes 32 symptomatic patients with muscle disease subdivided into two subgroups (a) 16 patients with acute inflammatory myositis; And (b)16 patients with hereditary myopathy. The patients will be subjected to neuromuscular ultrasound (US) and electrophysiology at baseline,after 6 months and after 12 months. The number and location of studied muscles will be determined according to pattern of clinical presentation.
The purpose of this study is to use a new MRI imaging coil developed for enhancing structures made of cartilage to determine if the device can produce improved images of the human larynx. In addition, if enhanced images can be obtained, a further purpose will be to determine if, in patients with laryngeal cancer, whether or not early invasion of cartilage can be detected. Patients with laryngeal cancer will be asked to undergone an MRI scan using this new image-enhancing coil to see if cartilage invasion can be detected. Patients will be followed during and after treatment to determine their ultimate response to treatment. No additional MRI scans for the purposes of this protocol will be performed other than the initial pretreatment scan.

We hope to determine if this new MRI imaging device can detect early cancer invasion of the laryngeal cartilages in patients with laryngeal cancer. Since this modality has never been attempted before on the human larynx, we are simply looking for the presence or absence of cartilage destruction. Both conventional CT and conventional MRI are poor at recongnizing this finding. High resolution MRI may allow the detection of this finding or it may not - detection of this finding is the endpoint.
Dosage: One 250 mg mefloquine hydrochloride tablet once weekly.

Prophylactic drug administration should begin 1 week before arrival in an endemic area. Subsequent weekly doses should be taken regularly, always on the same day of each week, preferably after the main meal. To reduce the risk of malaria after leaving an endemic area, prophylaxis must be continued for 4 additional weeks to ensure suppressive blood levels of the drug when merozoites emerge from the liver. Tablets should not be taken on an empty stomach and should be administered with at least 8 oz (240 mL) of water.

In certain cases, e.g., when a traveler is taking other medication, it may be desirable to start prophylaxis 2 to 3 weeks prior to departure, in order to ensure that the combination of drugs is well tolerated (see PRECAUTIONS: Drug Interactions).

When prophylaxis with mefloquine fails, physicians should carefully evaluate which antimalarial to use for therapy.
FIELD: organic chemistry, nucleosides. SUBSTANCE: invention involves optimally substituted N 6 -oxa-, thia-, thioxa- and azacyclo-alkyl-substituted derivatives of adenosine that are selective agonists of adenosine receptors of type-I. These compounds are potentially useful agents for treatment of patients with cardiovascular diseases and diorders of the central nervous system. Invention describes novel derivatives of adenosine of the general formula (I)   where R 1  means monocyclic hetero-cyclic group containing from 3 to 15 atoms and at least one of that is taken among the group consisting of N, O and SO 2  that can be mono- or poly-substituted with one or more substitutes taken among the group including oxo-group, hydroxyl, lower alkyl, substituted lower alkyl, acyl or carboxyl group where R 1  does not mean monocyclic lactam or imide and where R 1  does not contain epoxy-group. Invention describes also pharmaceutical composition and method of correction of electric disorders in mammal heart. EFFECT: new compounds indicated above, improved method of correction, valuable medicinal properties. 12 cl, 2 dwg, 2 tbl, 5 ex
Pulmonary infection is highly prevalent in patients with acute myocardial infarction undergoing percutaneous coronary intervention. However, the potential mechanism is not well characterized. Myocardial ischemia-reperfusion injury (MIRI) induces acute lung injury (ALI) related to pulmonary infection and inflammation. Recent studies have shown that pyroptosis mediates ALI in several human respiratory diseases. It is not known whether MIRI induces pyroptosis in the lungs. Furthermore, ticagrelor is a clinically approved anti-platelet drug that reduces ALI and inhibits the expression levels of several pyroptosis-associated proteins, but the effects of ticagrelor on MIRI-induced ALI have not been reported. Therefore, we investigated whether ticagrelor alleviated ALI in the rat MIRI model, and its effects on pyroptosis in the lungs. Sprague-Dawley rats were randomly divided into four groups: control, MIRI, MIRI plus low ticagrelor (30 mg/kg), and MIRI plus high ticagrelor (100 mg/kg). Hematoxylin and Eosin (HE) staining was performed on the lung sections, and the HE scores were calculated to determine the extent of lung pathology. The wet-to-dry ratio of the lung tissues were also determined. The expression levels of pyroptosis-related proteins such as NLRP3, ASC, and Cleaved caspase-1 were estimated in the lung tissues using the western blot. ELISA was used to estimate the IL-1β levels in the lungs. Immunohistochemistry was performed to determine the levels of MPO-positive neutrophils as well as the total NLRP3-positive and Cleaved caspase-1-positive areas in the lung tissues. The lung tissues from the MIRI group rats showed significantly higher HE score, wet-to-dry ratio, and the MPO-positive area compared to the control group, but these effects were attenuated by pre-treatment with ticagrelor. Furthermore, lung tissues of the MIRI group rats showed significantly higher expression levels of pyroptosis-associated proteins, including NLRP3 (2.1-fold, P < 0.05), ASC (3.0-fold, P < 0.01), and Cleaved caspase-1 (9.0-fold, P < 0.01). Pre-treatment with the high-dose of ticagrelor suppressed MIRI-induced upregulation of NLRP3 (0.46-fold, P < 0.05), ASC (0.64-fold, P < 0.01), and Cleaved caspase-1 (0.80-fold, P < 0.01). Immunohistochemistry results also confirmed that pre-treatment with ticagrelor suppressed MIRI-induced upregulation of pyroptosis in the lungs. In summary, our data demonstrated that MIRI induced ALI and upregulated pyroptosis in the rat lung tissues. Pre-treatment with ticagrelor attenuated these effects.